- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Safety Profile of Once-Weekly Subcutaneous Semaglutide in a Real-World Adult Population with T2D (Poster Halls B-C; [Board No. 797]) - Apr 10, 2023 - Abstract #ADA2023ADA_1387; A two-fold increase in level-2 hypoglycemia was associated with insulin use and microvasculopathy. No new safety concerns were observed with OW semaglutide in this large, diverse, RW population with T2D; the safety profile was in line with that of phase 3 trials of semaglutide.
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Mounjaro (tirzepatide) / Eli Lilly
Tirzepatide Reduces HbA1c and Body Weight Significantly More than Placebo or Semaglutide Irrespective of Baseline Beta-Cell Function (Poster Halls B-C; [Board No. 771]) - Apr 10, 2023 - Abstract #ADA2023ADA_1360; Tirzepatide (TZP), a once-weekly GIP/GLP-1 receptor agonist, achieved significantly greater HbA1c and body weight (BW) reductions with all doses (5, 10, 15 mg) vs placebo (SURPASS-1 [S-1]) and semaglutide (SEMA) 1 mg (SURPASS-2 [S-2]) in randomized Phase 3 trials in people with type 2 diabetes controlled by diet and exercise (S-1) or metformin (S-2)...BW reductions were greater across Qs with all TZP doses (ranging from 6%-14%) than placebo (up to 2%) or SEMA (up to 7%). TZP was more efficacious than placebo or SEMA in reducing HbA1c and BW across a spectrum of pancreatic beta-cell function, notably achieving greater glycemic improvement in people with markers of diminished pancreatic beta cell function at baseline.
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Trulicity (dulaglutide) / Eli Lilly
GLP-1 Receptor Agonists Dulaglutide and Semaglutide in Japanese Patients with Type 2 Diabetes (Poster Halls B-C; [Board No. 748]) - Apr 10, 2023 - Abstract #ADA2023ADA_1334; Gastrointestinal symptoms were observed in 13.2% of D and 46.3% of S (p<0.01). DTR-QoL scores related to pain and gastrointestinal symptoms were superior in D. This prospective trial demonstrated that S has more pronounced effects on glucose and BMI lowering, as well as a reduction in liver fat percentage and visceral fat area.
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Semaglutide Increases the Proportion of People with T2D Achieving a Metabolic Composite Endpoint (Poster Halls B-C; [Board No. 746]) - Apr 10, 2023 - Abstract #ADA2023ADA_1332; The proportion of participants reaching the composite endpoint across all trials was 24% and 32% for 0.5 mg and 1.0 mg semaglutide, respectively, vs 11% for comparators (p<0.0001). The results indicate that OW semaglutide may assist with the co-management of T2D and cardiometabolic risk factors, which could reduce the risk of CVD in people with T2D.
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk, cagrilintide (AM833) / Novo Nordisk
Effect of Coadministered s.c. Semaglutide and s.c. Cagrilintide on Glycemic Levels Measured by CGM (Ballroom 20D; [Board No. 54]) - Apr 10, 2023 - Abstract #ADA2023ADA_97; P2 The results indicate that OW semaglutide may assist with the co-management of T2D and cardiometabolic risk factors, which could reduce the risk of CVD in people with T2D. In total, 92 adult participants with T2D (HbA1c 7.5-10.0%), on metformin
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Trial initiation date, Trial primary completion date: ADJUST-T1D: ADJUnct Semaglutide Treatment in Type 1 Diabetes (clinicaltrials.gov) - Apr 7, 2023 P2, N=80, Not yet recruiting, In this phase 2 (NCT04982575), multicenter, double-blind trial, adults with T2D (HbA1c 7.5-10.0%) and BMI ?27 kg/m2 on metformin Initiation date: Jan 2023 --> Apr 2023 | Trial primary completion date: Nov 2024 --> Jul 2024
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Trulicity (dulaglutide) / Eli Lilly, Mounjaro (tirzepatide) / Eli Lilly
Review, Journal: Dual GIP/GLP-1 receptor agonists: new advances for treating type-2 diabetes. (Pubmed Central) - Apr 4, 2023 Because of the complementarity of action of the two incretins, tirzepatide showed better dose-dependent (5, 10 and 15mg) efficacy (greater reduction in HbA1c and body weight) than placebo, basal insulin or two GLP-1 analogues (dulaglutide and semaglutide) in the SURPASS program...Other original molecules have been built, including triple GIP/GLP-1/glucagon receptor agonists. The risk/benefit ratio will decide whether dual (or triple) receptor agonists should replace pure GLP-1 receptor agonists for the management of T2D in the near future, with a significant role in the pharmacotherapy of obesity.
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Trial primary completion date: A Research Study to Compare Two Semaglutide Medicines in People With Type 2 Diabetes (clinicaltrials.gov) - Mar 30, 2023 P3, N=332, Recruiting, Once weekly treatment with semaglutide and empagliflozine achieves a great reduction in HbA1c, and as such are safe for treatment of T2DM. Trial primary completion date: Feb 2023 --> Sep 2023
- |||||||||| Firsocostat (GS-0976) / Gilead, cilofexor/firsocostat (GS-9674/GS-0976) / Gilead, cilofexor (GS-9674) / Gilead
Trial completion date, Trial primary completion date: Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (clinicaltrials.gov) - Mar 30, 2023 P2, N=440, Recruiting, Trial primary completion date: Feb 2023 --> Sep 2023 Trial completion date: Mar 2024 --> Dec 2024 | Trial primary completion date: Mar 2024 --> Nov 2024
|